ArticleHeart views : the official journal of the Gulf Heart Association
Prognostic Value of Normal Triglyceride Levels among Patients with Target Low-density Lipoproteins Presenting with First Acute Coronary Syndrome.
Article in Heart views : the official journal of the Gulf Heart Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hypercholesterolemia, mainly low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs), is a major risk factor for coronary artery disease (CAD). The prognostic value of lowering LDL-C and TG in patients with CAD is well studied. We sought to examine the prognostic value of TG among patients presenting with acute coronary syndrome (ACS) and target LDL-C level. Methods: This is a retrospective study of patients admitted with first-presentation ACS. We included patients with first-presentation ACS who had lipid profiles measured within 3 months before the presentation. Patients with prior ACS, congenital heart disease, and those without baseline lipid profiles were excluded. Target LDL-C level was defined as LDL-C <1.8 mmol/L, and normal TG level was defined as <1.7 mmol/L. The study subjects were followed up for major adverse cardiac events (MACE) (cardiac death and nonfatal myocardial infarction [MI]). Results: Among the 7020 patients admitted with ACS, 393 met the inclusion criteria. Of whom, 106 (mean age: 70.3 ± 10.7 years, 76% of males) had target LDL-C level and were included. CAD risk factors were prevalent among the cohort. The mean total cholesterol, LDL-C, and TG were 3.6 ± 0.9, 1.4 ± 0.3, and 1.7 ± 1.5 mmol/L, respectively. Most patients presented with non-ST-elevation MI (54.7%), followed by unstable angina (36.8%). Over a median follow-up of 5.6 years, 17 (16%) patients had MACE, of which 14.2% were nonfatal MI and 1.9% of patients had cardiac death. There was no statistically significant difference in MACE between those with normal and high levels of TG. Conclusions: In this retrospective cohort of patients presenting with first-presentation ACS, TG level did not confer an increased risk of MACE among patients with target LDL-C level.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.